418 related articles for article (PubMed ID: 34398221)
1. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
[TBL] [Abstract][Full Text] [Related]
2. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
3. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
[TBL] [Abstract][Full Text] [Related]
5. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
6. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
8. Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Spelman T; Magyari M; Butzkueven H; Van Der Walt A; Vukusic S; Trojano M; Iaffaldano P; Horáková D; Drahota J; Pellegrini F; Hyde R; Duquette P; Lechner-Scott J; Sajedi SA; Lalive P; Shaygannejad V; Ozakbas S; Eichau S; Alroughani R; Terzi M; Girard M; Kalincik T; Grand'Maison F; Skibina O; Khoury SJ; Yamout B; Sa MJ; Gerlach O; Blanco Y; Karabudak R; Oreja-Guevara C; Altintas A; Hughes S; McCombe P; Ampapa R; de Gans K; McGuigan C; Soysal A; Prevost J; John N; Inshasi J; Stawiarz L; Manouchehrinia A; Forsberg L; Sellebjerg F; Glaser A; Pontieri L; Joensen H; Rasmussen PV; Sejbaek T; Poulsen MB; Christensen JR; Kant M; Stilund M; Mathiesen H; Hillert J;
Front Neurol; 2023; 14():1274194. PubMed ID: 38187157
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
11. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
14. Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2024 Jun; 271(6):3142-3152. PubMed ID: 38430270
[TBL] [Abstract][Full Text] [Related]
15. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
Hänninen K; Viitala M; Atula S; Laakso SM; Kuusisto H; Soilu-Hänninen M
J Neurol; 2022 Feb; 269(2):913-922. PubMed ID: 34170403
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
17. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
Hillert J; Tsai JA; Nouhi M; Glaser A; Spelman T
Mult Scler; 2022 Feb; 28(2):237-246. PubMed ID: 34080926
[TBL] [Abstract][Full Text] [Related]
20. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
